Rodman & Renshaw Initiates Coverage on Cleveland BioLabs (CBLI) with a Market Outperform
More News related to CBLI
- Cleveland BioLabs Opens Enrollment of Second Safety Study for CBLB502
- Cleveland BioLabs Publishes New Insights Into Mechanism of Action of Curaxins, Extending Their Clinical Potential
- Cleveland BioLabs to Present at Merriman 6th Annual Investor Summit
- Cleveland BioLabs to Host Roundtable on Protectan CBLB502 for Acute Radiation Syndrome
- Cleveland BioLabs to Present at 8th Annual BIO Investor Forum
Rodman & Renshaw initiates coverage on Cleveland BioLabs, Inc. (Nasdaq: CBLI) with a Market Outperform. Price target $8.
To see more analyst ratings on CBLI Click Here.
Cleveland Biolabs, Inc. engages in the discovery, development, and commercialization of products for cancer treatment and protection of normal tissues from radiation and other acute stresses.
Related Categories
New CoverageStocks Mentioned
+0.13Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
